Skip to main content

The risk and management of anaphylaxis in the setting of immunotherapy

Buy Article:

$44.50 plus tax (Refund Policy)


Anaphylactic events due to immunotherapy are probably not completely preventable. There is always an inherent risk surrounding the administration of an allergen to an individual who is sensitized to the substance administered.


There are, however, effective measures to reduce the risk of these events, and to optimize the assurance of a good outcome in the face of such an event.


Of prime importance in preventing these episodes is the regular assessment of the patient's health status, especially in regard to asthma, and the careful attention to the prevention of dosing errors.


Of equal importance, in regard to assuring a good outcome should such an event occur, are the rapid recognition of symptoms and the immediate injection of epinephrine, the drug of choice for the treatment of any episode of anaphylaxis.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: Anaphylaxis; anaphylaxis prevention; anaphylaxis treatment; epinephrine; immunotherapy; treatment

Document Type: Research Article

Affiliations: Allergy and Asthma Care, Germantown, Tennessee, USA

Publication date: 2012-11-01

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more